Safety gains don't translate into reduced costs or increased QALYs for doxycycline compared with prednisolone for patients with bullous pemphigoid

Sach, Tracey ORCID: https://orcid.org/0000-0002-8098-9220 (2018) Safety gains don't translate into reduced costs or increased QALYs for doxycycline compared with prednisolone for patients with bullous pemphigoid. British Journal of Dermatology, 178 (2). pp. 320-321. ISSN 0007-0963

Full text not available from this repository. (Request a copy)
Item Type: Article
Uncontrolled Keywords: cost-benefit analysis,doxycycline,humans,pemphigoid, bullous,prednisolone,quality-adjusted life years
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups: Faculty of Medicine and Health Sciences > Research Groups > Health Economics
Faculty of Medicine and Health Sciences > Research Groups > Norwich Clinical Trials Unit
Faculty of Medicine and Health Sciences > Research Groups > Public Health and Health Services Research
Depositing User: LivePure Connector
Date Deposited: 16 Jul 2020 23:47
Last Modified: 22 Oct 2022 06:30
URI: https://ueaeprints.uea.ac.uk/id/eprint/76154
DOI: 10.1111/bjd.16226

Actions (login required)

View Item View Item